Vasu Vaccines & Speciality Drugs Profile
Key Indicators
- Authorised Capital ₹ 1.25 Cr
as on 16-01-2025
- Paid Up Capital ₹ 1.00 Cr
as on 16-01-2025
- Company Age 7 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 135.00 Cr
as on 16-01-2025
- Revenue 12.45%
(FY 2023)
- Profit -126.97%
(FY 2023)
- Ebitda -0.09%
(FY 2023)
- Net Worth -35.76%
(FY 2023)
- Total Assets -82.43%
(FY 2023)
About Vasu Vaccines & Speciality Drugs
- CIN/LLPIN
U51909TG2017PTC120802
- Company No.
120802
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Nov 2017
- Date of AGM
08 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Vasu Vaccines & Speciality Drugs?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Abhinay Bejgam  | Managing Director | 27-Jun-2020 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Srinivas Bejgam | Director | 27-Jun-2020 | Current |
| Arvind Venkat | Nominee Director | 02-Apr-2018 | Current |
Financial Performance of Vasu Vaccines & Speciality Drugs.
Vasu Vaccines & Speciality Drugs Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 12.45% increase. The company also saw a substantial fall in profitability, with a 126.97% decrease in profit. The company's net worth observed a substantial decline by a decrease of 35.76%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Vasu Vaccines & Speciality Drugs?
In 2023, Vasu Vaccines & Speciality Drugs had a promoter holding of 100.00%. The company had 2 Subsidiaries. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Medchem International India Private LimitedActive 6 years 3 monthsSrinivas Bejgam and Abhinay Bejgam are mutual person
Vasu Organics Private LimitedActive 10 years 10 monthsSrinivas Bejgam and Abhinay Bejgam are mutual person
Venkatasai Agencies Drugs Private LimitedActive 2 years 10 monthsSrinivas Bejgam is a mutual person
- Vasu Vaccines And Speciality Drugs Hyd Private LimitedActive 2 years 10 months
Srinivas Bejgam and Abhinay Bejgam are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 09 May 2022 | ₹50.00 Cr | Satisfied |
Hdfc Bank Limited Creation Date: 14 Mar 2018 | ₹85.00 Cr | Satisfied |
How Many Employees Work at Vasu Vaccines & Speciality Drugs?
Vasu Vaccines & Speciality Drugs has a workforce of 143 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vasu Vaccines & Speciality Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vasu Vaccines & Speciality Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
